Plain-English translation of NCT04216121 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing whether adding local ablative therapy (focused radiation or heat treatments) to specific cancer spots can help patients whose lung cancer has started growing again while taking osimertinib. You would continue taking osimertinib while receiving these targeted treatments to 3 or fewer areas of new or growing cancer. The goal is to see if combining both approaches helps patients live longer and stay healthier.
Even when this medication works well at first, some patients develop a few spots of cancer that start growing again while the rest of their disease stays controlled. Doctors want to know if treating just those few spots with focused radiation, while continuing the medication, can help patients avoid switching to chemotherapy or other treatments.
You would continue taking osimertinib as you have been, and when your doctor confirms that a few spots of cancer are growing, you would receive local ablative therapy (such as radiation or radiofrequency ablation) targeted at those specific spots. The research team will monitor you with imaging scans and clinical visits to track how you respond to the combined approach. The study expects to enroll about 39 patients and will document whether this strategy helps delay the need for other cancer treatments.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
Belgium
Sponsor
Universitaire Ziekenhuizen KU Leuven
Enrollment target
~39 participants
Started
May 2021
Primary completion
October 2025
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Patrick Berkovic, MD
Universitaire Ziekenhuizen KU Leuven